Swedish Orphan Biovitrum AB (Sobi) today published its Annual Report for 2012,
themed "Building value for patients, partners and shareholders", on the
company's website, www.sobi.com.
The report encompasses the company's approach to keeping the patient journey -
from diagnosis and treatment, to on-going disease management and long-term
outcomes - at the centre of how it prioritises its capabilities and investments.
By creating and maintaining a dialogue with key stakeholders (patients
organizations, physicians, governments and payers), Sobi seeks to ensure that
treatments are delivered in a sustainable way. Sobi refers to this approach as
Patient and Customer Centric commercialisation.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not for publication
Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
Investor Relations
T: +46 70 410 71 80 T: +1 347 224 0819
oskar.bosson@sobi.com jorgen.winroth@sobi.com
[HUG#1690373]
